{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670318423945216.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/art.24463"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.24463"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.24463"}}],"dc:title":[{"@value":"Comparison of drug retention rates and causes of drug discontinuation between anti–tumor necrosis factor agents in rheumatoid arthritis"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of severe rheumatoid arthritis (RA), yet drug discontinuation is common. The aim of this study was to compare treatment retention rates and specific causes of anti‐TNF discontinuation in a population‐based RA cohort.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>All patients treated with etanercept, infliximab, or adalimumab within the Swiss Clinical Quality Management RA cohort between 1997 and 2006 were included in the study. Causes of treatment discontinuation were broadly categorized as adverse events (AEs) or nontoxic causes, and further subdivided into specific categories. Specific causes of treatment interruption were analyzed using a Cox proportional hazards model and adjusted for potential confounders.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 2,364 anti‐TNF treatment courses met the inclusion criteria. Treatment discontinuation was reported 803 times: 309 with etanercept, 249 with infliximab, and 245 with adalimumab. Drug inefficacy represented the largest single cause of treatment discontinuation (55.8% of cases). The median time of receiving anti‐TNF therapy was 37 months, but discontinuation rates differed between the 3 anti‐TNF agents (<jats:italic>P</jats:italic> < 0.001), with shorter retention rates for infliximab (hazard ratio [HR] 1.24, 99% confidence interval [99% CI] 1.01–1.51). The specific causes of treatment discontinuation revealed an increased risk of AEs with infliximab (HR 1.4, 99% CI 1.003–1.96), mostly due to an increased risk of infusion or allergic reactions (HR 2.11, 99% CI 1.23–3.62). Other discontinuation causes were equally distributed between the anti‐TNF agents.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In this population, infliximab was associated with higher overall discontinuation rates compared with etanercept and adalimumab, which is mainly due to an increased risk of infusion or allergic reactions.</jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670318423945217","@type":"Researcher","foaf:name":[{"@value":"Sophie Martin Du Pan"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318423945219","@type":"Researcher","foaf:name":[{"@value":"Silvia Dehler"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318423945220","@type":"Researcher","foaf:name":[{"@value":"Adrian Ciurea"}]},{"@id":"https://cir.nii.ac.jp/crid/1380579818030439680","@type":"Researcher","foaf:name":[{"@value":"Hans‐Rudolf Ziswiler"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318423945216","@type":"Researcher","foaf:name":[{"@value":"Cem Gabay"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318423945221","@type":"Researcher","foaf:name":[{"@value":"Axel Finckh"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"08937524"},{"@type":"EISSN","@value":"15290123"},{"@type":"PISSN","@value":"https://id.crossref.org/issn/00043591"}],"prism:publicationName":[{"@value":"Arthritis Care & Research"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2009-04-29","prism:volume":"61","prism:number":"5","prism:startingPage":"560","prism:endingPage":"568"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.24463"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.24463"}],"createdAt":"2009-04-29","modifiedAt":"2023-10-10","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050003825007705344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-"},{"@value":"Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis—the ANSWER cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1050012570392144896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1050018218946011264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1050287297263335552","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules"}]},{"@id":"https://cir.nii.ac.jp/crid/1050299693922695424","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1050299693922723072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1050575520345485312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study"},{"@value":"Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1050581168899429120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis - The ANSWER cohort study"},{"@value":"Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002217661110272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004239703084160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Longterm Retention Rate and Risk Factor for Discontinuation Due to Insufficient Efficacy and Adverse Events in Japanese Patients with Rheumatoid Arthritis Receiving Etanercept Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004239703172352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142672448000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025430637861248","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER cohort"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706267202048","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Improved safety of biologic therapy for rheumatoid arthritis over the 8-year period since implementation in Japan: long-term results from a multicenter observational cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643830265216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664133262592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861704780544384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JAK inhibitors in rheumatology"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814753560704","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Trends of disease activity in Japanese patients over 75 years with rheumatoid arthritis from 2014 to 2021: the ANSWER cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814753568256","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205178316416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Theory-based Analysis of the Anti-inflammatory Effect of TNF Inhibitors on Rheumatoid Arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390860929791615104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora<sup>®</sup> 30 ‍mg Syringes for S.C. Injection), the first Nanobody<sup>®</sup> compound in Japan"},{"@language":"ja","@value":"国内初のナノボディ<sup>®</sup>製剤オゾラリズマブ（ナノゾラ<sup>®</sup>皮下注30 ‍mgシリンジ）の薬理学的特徴及び臨床試験成績"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/art.24463"},{"@type":"CROSSREF","@value":"10.1093/rheumatology/ker221_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.3899/jrheum.130901_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1186/s13075-020-02232-w_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1254/fpj.23051_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1093/rheumatology/keaf157_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1007/s10067-016-3201-5_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.2133/dmpk.dmpk-13-rg-090_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1007/s10067-021-05609-7_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1186/s13075-021-02496-w_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1093/mr/roab003_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1136/rmdopen-2023-003160_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1007/s00296-020-04660-y_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.3109/03009742.2012.762037_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0216624_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1038/s41598-021-04075-0_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1080/25785826.2023.2172808_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1093/rheumatology/kead539_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1093/rheumatology/keae081_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1136/annrheumdis-2011-200838_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.3899/jrheum.151006_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"},{"@type":"CROSSREF","@value":"10.1186/s13075-019-1880-4_references_DOI_a8mP3Kw8wI3ItAhWHLmZvbrJhhU"}]}